NDA 012209 · Spectrum Pharms
Fluorouracil
Fluorouracil · Injection
NovelPriority reviewOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Jul 29, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1962
Apr 25, 1962
Approved uses
2
Original approval plus efficacy supplements
Registered trials
4,755
1,167 Phase 3, 630 recruiting
FAERS reports
77,613
73,672 serious, 10,971 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 29, 2016 Supplement 40 · Efficacy LetterLabel
- Apr 25, 1962 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- FLUOROURACIL · FLUOROURACIL 2.5GM/50ML (50MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- FLUOROURACIL · FLUOROURACIL 500MG/10ML (50MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluorouracil" as an intervention, any sponsor and status, largest first.
- Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and IIIPivotal-lookingStatus unknown
State Key Laboratory of Cancer BiologyResearch network
NCT01196260 · 8,000 participants (planned) · Start Jan 2004 · Primary completion Dec 2020
Drug: Capecitabine and Oxaliplatin · For: Colorectal Cancer
Sites: Xi'an, China
- Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph NodesPivotal-lookingCompleted
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00433589 · 6,600 participants (planned) · Start Feb 2007 · Primary completion Mar 2020
Drug: anthracycline-based; docetaxel and capecitabine and 2 more · For: Breast Cancer
Sites: Amsterdam, Netherlands
- Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal CancerPivotal-lookingCompleted
Cancer Research UK, GlasgowAcademic, hospital or other
NCT00749450 · 6,088 participants · Start Mar 2008 · Primary completion Nov 2017
Drug: capecitabine; fluorouracil and 1 more · For: Colorectal Cancer
Sites: Glasgow, United Kingdom
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerPivotal-lookingCompleted
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00002582 · 6,000 participants (planned) · Start Jun 1993
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom; Glasgow, United Kingdom
- Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II EvaluationPivotal-lookingStatus unknown
Technische Universität DresdenAcademic, hospital or other
NCT04089631 · 4,812 participants (planned) · Start Jun 26, 2020 · Primary completion Jun 2023
Drug: Capecitabine · For: Colon Cancer Stage II
Sites: Dresden, Germany
- A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01358877 · 4,804 participants · Start Nov 8, 2011 · Primary completion Dec 19, 2016
Drug: 5-Fluorouracil; Carboplatin and 8 more · For: Breast Cancer
Sites: Scottsdale, Arizona; Everett, California; Greenbrae, California · 546 sites in all
- Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade LesionsPivotal-lookingCompleted
AIDS Malignancy ConsortiumResearch network
NCT02135419 · 4,446 participants · Start Sep 24, 2014 · Primary completion Aug 6, 2021
Drug: imiquimod; fluorouracil · For: Anal Cancer; High-grade Squamous Intraepithelial Lesion; HIV Infection and 1 more
Sites: Los Angeles, California; Palm Springs, California; San Francisco, California · 25 sites in all
- Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By SurgeryPivotal-lookingStatus unknown
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00301925 · 4,400 participants (planned) · Start Dec 16, 2005 · Primary completion Sep 2024
Drug: pegfilgrastim; capecitabine and 4 more · For: Breast Cancer
Sites: Ashford-Kent, United Kingdom; Ashington, United Kingdom; Ashton-under-Lyne, United Kingdom · 152 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea7,077
- neutropenia5,294
- nausea5,064
- vomiting4,038
- off label use3,620
- neuropathy peripheral3,541
- fatigue3,320
- disease progression3,293
- pyrexia3,085
- thrombocytopenia3,036
- febrile neutropenia2,915
- anaemia2,610
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,695 |
| 2005 | 1,687 |
| 2006 | 1,392 |
| 2007 | 1,586 |
| 2008 | 1,848 |
| 2009 | 1,815 |
| 2010 | 1,692 |
| 2011 | 2,338 |
| 2012 | 2,862 |
| 2013 | 2,240 |
| 2014 | 1,878 |
| 2015 | 2,385 |
| 2016 | 2,753 |
| 2017 | 3,198 |
| 2018 | 4,845 |
| 2019 | 5,110 |
| 2020 | 4,266 |
| 2021 | 4,273 |
| 2022 | 5,711 |
| 2023 | 6,300 |
| 2024 | 5,981 |
| 2025 | 6,681 |
| 2026 | 5,077 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fluorouracil* (Fluorouracil)
2024 spending
$45.6M
Beneficiaries
583,453
677,948 claims
Per beneficiary
$78
$1.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $48,774,660 |
| 2021 | $52,372,839 |
| 2022 | $55,041,064 |
| 2023 | $52,836,157 |
| 2024 | $45,569,059 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE, Homann N, Pauligk C, et al. · Lancet 2019 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Wang-Gillam A, Li CP, Bodoky G, et al. · Lancet 2016 · Clinical Trial, Phase III, Multicenter Study
- Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Vermorken JB, Mesia R, Rivera F, et al. · N Engl J Med 2008 · Clinical Trial, Phase III, Multicenter Study
- Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Conroy T, Galais MP, Raoul JL, et al. · Lancet Oncol 2014 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, et al. · Lancet Oncol 2020 · Clinical Trial, Phase III, Comparative Study
- Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Forastiere AA, Goepfert H, Maor M, et al. · N Engl J Med 2003 · Clinical Trial, Multicenter Study
Sponsor: Spectrum Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.